Unknown

Dataset Information

0

TP53 and the star-crossed lovers MDS and AML.

ABSTRACT:

SUBMITTER: Welch JS 

PROVIDER: S-EPMC9012128 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

TP53 and the star-crossed lovers MDS and AML.

Welch John S JS  

Blood 20220401 15

Similar Datasets

Unknown Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cells.
| S-EPMC11216995 | biostudies-literature
Unknown TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.
| S-EPMC9092405 | biostudies-literature
Unknown Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type
| S-EPMC12395695 | biostudies-literature
Unknown Impact of TP53 mutation on genetic and cellular hierarchy profile in complex karyotype AML/MDS with increased blasts.
| S-EPMC11568287 | biostudies-literature
Unknown Integrated genetic, epigenetic, and immune landscape of <i>TP53</i> mutant AML and higher risk MDS treated with azacitidine.
| S-EPMC11180421 | biostudies-literature
Unknown MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities
| S-EPMC12914417 | biostudies-literature
Unknown Quantitative analyses of DAPK1 methylation in AML and MDS.
| S-EPMC3463871 | biostudies-literature
Unknown Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
| S-EPMC10656725 | biostudies-literature
Unknown Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro.
| S-EPMC7335335 | biostudies-literature
Unknown HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML.
| S-EPMC7521497 | biostudies-literature